Shaff Eric D.
Known title: CEO and PresidentCIK: 0001643734
Associated companies
Transaction History
| MCRB | ▼ Sell | Open Market | 263 | $1K | 8/17/2026 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 722 | — | 8/15/2026 | View on chart |
| MCRB | ▼ Sell | Open Market | 259 | $2K | 5/18/2026 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 722 | — | 5/15/2026 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 723 | — | 2/15/2026 | View on chart |
| MCRB | ▼ Sell | Open Market | 259 | $2K | 2/15/2026 | View on chart |
| MCRB | ▼ Sell | Open Market | 217 | $4K | 11/15/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 331 | — | 11/15/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 390 | — | 11/15/2025 | View on chart |
| MCRB | ▼ Sell | Open Market | 217 | $4K | 8/18/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 391 | — | 8/15/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 333 | — | 8/15/2025 | View on chart |
| MCRB | ▼ Sell | Open Market | 220 | $2K | 5/16/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 390 | — | 5/15/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 331 | — | 5/15/2025 | View on chart |
| MCRB | ▼ Sell | Open Market | 12,726 | $10K | 2/18/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 26,563 | — | 2/15/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 7,813 | — | 2/15/2025 | View on chart |
| MCRB | ▼ Sell | Open Market | 2,505 | $1K | 11/18/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 7,812 | — | 11/15/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 8,748 | $6K | 10/28/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 27,837 | $0 | 10/27/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 2,518 | $2K | 8/16/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 7,813 | — | 8/15/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 7,812 | — | 5/15/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 2,435 | $2K | 5/15/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 11,549 | $12K | 2/16/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 31,250 | — | 2/15/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 8,552 | $12K | 10/30/2023 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 27,838 | $0 | 10/27/2023 | View on chart |
| MCRB | ▲ Buy | Grant | 63,492 | $200K | 7/5/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
MCRB to Present Preclinical Data on SER-428 at IDWeek 2026
Seres Therapeutics announced it will present preclinical data for SER-428, an investigational live biotherapeutic intended to reduce the risk of bloodstream infections in critically ill patients, at the upcoming IDWeek 2026 conference. The data will focus on early-stage results that support the development of the oral liquid LBP. The stock is currently trading near its $7.60 support level with an RSI of 22.8, indicating limited recent price momentum.
MCRB to Present Preclinical Data on SER-428 at IDWeek 2026. Seres Therapeutics announced it will present preclinical data for SER-428, an investigational live biotherapeutic intended to reduce the risk of bloodstream infections in critically ill patients, at the upcoming IDWeek 2026 conference. The data will focus on early-stage results that support the development of the oral liquid LBP. The stock is currently trading near its $7.60 support level with an RSI of 22.8, indicating limited recent price momentum.